Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · Healing & Recovery

TB-500 vs Thymosin-α1

TB-500 and Thymosin-α1 share a thymic origin but solve entirely different problems. TB-500 is a synthetic analog of Thymosin-β4 (an actin-binding protein). Thymosin-α1 is a 28-amino-acid peptide that matures T-cells. The shared word hides opposite mechanisms.

Bangkok research desk ·

Side-by-side

TB-500 Thymosin-α1
MechanismActin polymerisation, angiogenesis, cell migration.T-cell maturation; Th1 polarisation.
Half-lifeShort plasma; cumulative tissue effects.~2 hours plasma; persistent downstream effects.
Dose2-2.5 mg twice weekly SC.1.6 mg twice weekly SC.
Cycle4-6 weeks loading, maintenance thereafter.4-8 weeks typically.
Research contextMyocardial, dermal, musculoskeletal repair1.Hepatitis B and oncology adjuvant; registered clinical use2.
Cost tierMid.Mid-to-high.

TB-500 and Thymosin-α1 are often confused because of the shared "thymosin" root. The two peptides were both originally identified in thymic tissue, but they are biochemically unrelated and work on different systems12.

TB-500 is a synthetic fragment of Thymosin-β4, which sequesters actin monomers and modulates cytoskeletal dynamics. The downstream effect in research models is angiogenesis, cell migration, and tissue repair across myocardial, dermal, and musculoskeletal substrates. Research protocols use twice-weekly loading at 2-2.5 mg followed by a lower maintenance dose.

Thymosin-α1 is a 28-amino-acid peptide with a completely different functional role. It drives T-cell maturation, polarises the Th1 cytokine profile, and has registered clinical use in hepatitis B and as an oncology adjuvant in more than 30 countries. Research doses sit at 1.6 mg twice weekly subcutaneously.

A researcher studying tissue repair selects TB-500. A researcher studying immune modulation, chronic viral infection, or oncology adjunct use selects Thymosin-α1. Stacking is uncommon in the literature because the endpoints rarely overlap; the two peptides are independent tools sharing only a name. For the depth on TB-500, see TB-500 research history. For category-level context, see best peptides for healing and recovery.

Frequently asked

Are TB-500 and Thymosin-α1 related?
They share a thymic origin and the "thymosin" root in the name, but they are biochemically and functionally unrelated. TB-500 is a Thymosin-β4 fragment (cytoskeletal peptide). Thymosin-α1 is a 28-amino-acid T-cell maturation peptide.
Which has registered clinical use?
Thymosin-α1 is registered in more than 30 countries for hepatitis B and used as an oncology adjuvant2. TB-500 remains a research peptide with no clinical registration.
Is there a reason to use both?
Rarely. A research protocol with both a tissue-repair endpoint and an immune-modulation endpoint might employ both, but the rationale should be specific to the experimental design. The peptides do not amplify each other at any shared pathway.
Research desk
Ordering both TB-500 and Thymosin-α1 for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012. PMID: 22074294
  2. King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016. PMID: 27450734

All references verified against PubMed via NCBI E-utilities.